Plus   Neg

COMPASS Pathways Prices Upsized IPO At $17/Shr, Above Expected Range

COMPASS Pathways plc announced the pricing of upsized initial public offering of 7.5 million American Depositary Shares or ADSs, representing 7.5 million ordinary shares at $17 per ADS for total gross proceeds of $127.5 million.

COMPASS Pathways has filed to sell 6.7 million ADSs in the offering at price expected to be between $14.00 and $16.00 per ADS, and the underwriters have an option for 30 days to purchase up to 1.005 million additional ADSs.

The ADSs are expected to begin trading on Nasdaq on September 18, 2020 under the ticker symbol "CMPS." The offering is expected to close on or about September 22, 2020.

COMPASS has granted the underwriters a 30-day option to purchase up to an additional 1.125 million ADSs at the initial public offering price, less underwriting discounts and commissions.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. tech giant Google is laying the groundwork for a fiber-optic network that will connect the first time through Saudi Arabia and Israel, opening a new global internet traffic corridor, the Wall Street Journal reported, citing people familiar with the plans. The link would be established as part of an optical-fiber cable line connecting Europe with India. U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients.
Follow RTT